933-80-2 Usage
Description
4,5-Pyrimidinediamine, 6-chloro-2-methylis an organic compound that serves as an intermediate in the synthesis of selective inhibitors of Class I Phosphatidylinositol 3-Kinases. It is characterized by the presence of a pyrimidine ring with two amine groups at the 4 and 5 positions, a chlorine atom at the 6 position, and a methyl group at the 2 position. This unique structure makes it a valuable component in the development of pharmaceuticals targeting specific biological pathways.
Uses
Used in Pharmaceutical Industry:
4,5-Pyrimidinediamine, 6-chloro-2-methylis used as a key intermediate in the synthesis of selective inhibitors for Class I Phosphatidylinositol 3-Kinases. These inhibitors are important for the development of drugs targeting various diseases, including cancer and immune disorders, due to the crucial role of PI3Ks in cell growth, survival, and metabolism. 4,5-Pyrimidinediamine, 6-chloro-2-methyl-'s specific structure allows for the creation of targeted therapies with fewer side effects and increased efficacy.
Check Digit Verification of cas no
The CAS Registry Mumber 933-80-2 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 9,3 and 3 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 933-80:
(5*9)+(4*3)+(3*3)+(2*8)+(1*0)=82
82 % 10 = 2
So 933-80-2 is a valid CAS Registry Number.
933-80-2Relevant articles and documents
TRANSGLUTAMINASE 2 (TG2) INHIBITORS
-
Paragraph 001007, (2020/03/02)
Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit transglutaminase 2 (TG2). Also described herein are methods for using such TG2 inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from TG2 inhibition.
COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
-
Paragraph 0271, (2019/01/10)
The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for the treatment and/or prevention of neurodegenerative disease, mitchonodrial disease, fibrosis, and/or cardiomyopathy.
TANK-BINDING KINASE INHIBITOR COMPOUNDS
-
Page/Page column 167, (2015/12/24)
Compounds having the following formula (I) and methods of their use and preparation are disclosed:
